Pexacerfont
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Pexacerfont (
Bristol-Myers Squibb which acts as a CRF1
antagonist.
Corticotropin-releasing factor (CRF), also known as
stomach ulcers[citation needed], anxiety, depression, and development of high blood pressure and consequent cardiovascular problems.[2]
Pexacerfont is a recently developed CRF-1 antagonist which was in clinical trials for the treatment of anxiety disorders,[3] and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome.[citation needed]
A recent multicenter, randomized, double-blind, placebo-controlled trial found that pexacerfont (100 mg/day) did not separate from placebo on the primary outcome measure (the mean change from baseline to end point in the
Hamilton Anxiety Scale score).[4]
These results suggest that blockade of CRF1 receptor may not be a feasible treatment for anxiety disorders in certain human populations.
See also
- Corticotropin releasing hormone antagonists
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 59" (PDF). World Health Organization. p. 60. Retrieved 16 July 2016.
- S2CID 7731338.
- ^ Clinical trial number NCT00481325 for "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder" at ClinicalTrials.gov
- S2CID 5370614.